In the last few years, China has seen a major boom in innovative drug development, and the pharmaceutical industry in China has been rapidly transitioning from a generic drug-focused industry to an innovative drug development industry. This is partly fueled by a wave of "returnees” – Chinese-born scientists who were trained in the West and then migrated back to China to help jump start the life science industry in China. It is also attributed to the fundamental cultural change at the China FDA (CFDA), which has implemented a series of policies to improve drug development data quality and drug quality and reward innovation. As a result, several China-based biotech companies have discovered a number of world-class innovative drug candidates that have been licensed by several global companies – one example is Nanjing Legand’s CAR-T therapy that was licensed by Johnson & Johnson for $350 million upfront.
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey. The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein. The new facility will enhance WuXi's integrated testing service portfolio enabling drug developers to accelerate their projects from labs to patients.
The expansion will double total operation space to more than 115,000 square feet, and will create over 200 jobs. After the expansion, LTD's combined New Jersey operation will be one of the largest laboratories for preclinical and clinical drug development testing in the United States.
We are pleased to announce the expansion of our New Jersey facility. This addition expands upon our established Plainsboro facility, offering DMPK/ADME discovery and developmental studies to human pharma, animal health and agrochemical sectors. Through our expansion efforts, we will be converting our present Plainsboro lab into a fully regulated Bioanalytics facility with doubled space. We have planned a grand opening ceremony on Wednesday, April 18th. We would be delighted if you could join and celebrate with us.
WuXi AppTec has continued to build a comprehensive offering through organic growth and acquisition. Its Laboratory Testing Division is poised to play a key role in propelling the open-access capability and technology platform company forward with a full range of integrated testing services. As an organization, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.
China is determined to become a larger player in the pharmaceutical market, and offering more opportunities for cross-border collaboration.
In terms of cross-border collaboration in the pharmaceutical business, Dr. Francis Tse, CSO of Laboratory Testing Division at WuXi AppTec, said collaboration between the West and emerging markets, specifically China and India, are most noteworthy. "China is determined to be a major player," said Tse, noting the country's new set of drug approval policies. The Chinese government and the China Food and Drug Administration (CFDA) are starting an advisory committee, following an American example, Tse explained. China was also acknowledged as a regulatory member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in June of 2017.